Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study
Journal
Japanese journal of clinical oncology
Journal Volume
51
Journal Issue
3
Pages
345-353
Date Issued
2021
Author(s)
Shao Z.
Tseng L.-M.
Pang D.
Yang Y.
Li W.
Liao N.
Geng C.
Zhang Q.
Xu B.
Liu D.
Kwong A.
et al (continued in the appendix)
Abstract
Background: The addition of pertuzumab to trastuzumab plus standard chemotherapy as adjuvant therapy following surgery significantly improved invasive disease-free survival (IDFS) in patients with HER2-positive early breast cancer in the multinational ran
Subjects
adjuvant; breast cancer; Chinese; HER2; pertuzumab
SDGs
Other Subjects
pertuzumab; placebo; trastuzumab; antineoplastic agent; epidermal growth factor receptor 2; monoclonal antibody; pertuzumab; trastuzumab; adjuvant chemotherapy; adult; aged; Article; China; Chinese; clinical outcome; clinical trial; demography; diarrhea;
Publisher
NLM (Medline)
Type
journal article